Development of strategies for antitumor immunomodulation

• Grant number: 15/01488-2
• Support Opportunities: Regular Research Grants
• Start date: September 01, 2015
• End date: August 31, 2017
• Field of knowledge: Biological Sciences - Immunology
• Principal Investigator: Marcio Chaim Bajgelman
• Grantee: Marcio Chaim Bajgelman
• Host Institution: Centro Nacional de Pesquisa em Energia e Materiais (CNPEM). Campinas , SP, Brazil

Abstract

Here we propose a new platform for antitumor immunotherapy based on the use of nanoparticles. These particles are engineered to interact with specific receptors on target cells in order to drive the tropism. In this proposal we plan to explore new nanoparticle formulations harboring different ligands to evaluate tropism selectivity and immunomodulatory properties. We also propose to generate in vitro assays to explore these combinations. The best nanoparticle candidates will be tested in vivo, using immunocompetent animals challenged with syngeneic tumors. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

PALAMETA, SOLEDAD; MANRIQUE-RINCON, ANDREA J.; TOSCARO, JESSICA M.; SEMIONATTO, ISADORA F.; FONSECA, MATHEUS C.; ROSA, RHUBIA S. M.; RUAS, LUCIANA P.; OLIVEIRA, PAULO S. L.; BAJGELMAN, MARCIO C.. Boosting antitumor response with PSMA-targeted immunomodulatory VLPs, harboring costimulatory TNFSF ligands and GM-CSF cytokine. MOLECULAR THERAPY-ONCOLYTICS, v. 24, p. 13-pg., 2022-03-17. (15/01488-2, 19/04458-8)

MANRIQUE-RINCON, ANDREA J.; BERALDO, CAMILA M.; TOSCARO, JESSICA M.; BAJGELMAN, MARCIO C.. Exploring Synergy in Combinations of Tumor-Derived Vaccines That Harbor 4-1BBL, OX40L, and GM-CSF. FRONTIERS IN IMMUNOLOGY, v. 8, SEP 19 2017. (15/01488-2, 12/13132-0, 13/02041-6)